Communiqués Microba Life Sciences Limited

Actions

MAP

AU0000209868

Installations et services en soins de santé

Temps Différé Australian S.E. 02:30:50 27/08/2026			Varia. 5j.	Varia. 1 janv.
0,0580 ^AUD	+5,45%		0,00%	-23,68%

16/07	Transcript : Microba Life Sciences Limited, Q4 2026 Earnings Call, Jul 16, 2026
16/06	Transcript : Microba Life Sciences Limited - Shareholder/Analyst Call

Communiqués

01/05	Bell Potter rates MAP as Speculative Buy	AQ
30/01	Morgans rates MAP as Speculative Buy	AQ
30/01	Bell Potter rates MAP as Speculative Buy	AQ
30/10/25	Bell Potter rates MAP as Speculative Buy	AQ
15/05/25	?Microba Announces Landmark GI Study Results From Over 4,600 Patients	AQ
15/05/25	Microba Announces Landmark GI Study Results From Over 4,600 Patients	BU
01/05/25	Morgans rates MAP as Speculative Buy	AQ
29/04/25	Microba Delivers Landmark IBD Results & Signs Major Gastro Partner	BU
05/07/23	First Distribution Agreement Executed with Sonic Healthcare	BU
28/06/23	Microba Commences Phase I Clinical Trial for IBD Therapeutic	BU
28/02/23	Microba Launches Next Generation Healthcare Testing	BU
29/11/22	Sonic Healthcare Acquires Strategic Stake in Microba Life Sciences, Establishes Significant Commercial Partnership	BU
28/10/22	SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME	BU
20/07/22	Microba Life Sciences : Investor Update - Q4 FY22 Results	PU
20/07/22	Microba Life Sciences : Q4 FY22 Quarterly Activities Report & Appendix 4C	PU
15/06/22	Microba Life Sciences : Application for quotation of securities - MAP	PU
26/05/22	Microba Life Sciences Signs Partnership With Nib-Backed Midnight Health	BU
05/05/22	Microba Accelerates Cancer Program With New Leads	BU
29/04/22	Microba Life Sciences : International Conference Presentation	PU
13/04/22	Microba Life Sciences : CSO presents to US industry conference	PU
06/04/22	Microba Appoints Therapeutics Head	BU
05/04/22	Microba Completes Successful IPO	BU